Tumors associated with a poor depth of response had a significantly reduced abundance of meta-cluster 1, which was characterized by elevated CD45 and low survival protein BCL-2 along with elevated IKZF3, MYC and IkBα, suggesting that phenotypic meta-cluster 1 may be responsive to MM therapy. The gene discussed is BCL2; the disease is Miyoshi myopathy.